Skip to Content
scroll

Clarity Pharmaceuticals Ltd (CU6)

ASX.CU6 $2.68

20 MINUTE DELAYED

14 DAYS FREE ACCESS

Join Market Matters and get full access
to all our Opinion + Action

LEARN MORE

CU6 $2.68

20 MINUTE DELAYED

TODAY

2.29 %

1 YEAR RETURN

0.00%

VOLUME

306,163

DIV YIELD

0%

PE RATIO

0.00

52 WEEK RANGE

0.68

2.98

ANALYSIS

i

SHARE PRICE ACTIVITY
Last (Price)

2.68

Change

0.06 (2.29)

Bid / Ask

2.66 - 2.70

Volume

306,163

Turnover

821,702

Open

2.65

Day Range

2.63 - 2.71

VWAP

2.68

Prev Close

2.62

Last Trade

21/02 4:10pm (AEST)

i

KEY INFORMATION
Sector

Shares Issued

NTA/Share

0.00

Last Dividend

0.00

Dividend Ex Date

0

Dividend Pay Date

0

i

BROKER CALLS

current

Mean

0.00

Target Price

0.00

i

CURRENT ()
Revenue

EBITDA

Profit

Earnings Per Share (EPS)

0

Dividend Per Share (DPS)

0

Yield %

0.00

Market Cap

0

Price to Earnings Ratio (P/E)

0

i

TARGET PRICE FORECAST

i

ESTIMATES ()
Revenue

0.00

EBITDA

0.00

Profit

0.00

Earnings Per Share (EPS)

0.00

Dividend Per Share (DPS)

0.00

i

BROKER CONSENSUS RECOMMENDATION

BUY

SELL

Target Price

0.00

Lt Growth Rate

0.00

Recommendation ()

0.00
image description

Business Summary

Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing products to address the growing need for the use of radiopharmaceuticals in oncology. It is developing targeted copper theranostics-based on its SAR Technology Platform for the treatment of cancer in children and adults. Its lead radiopharmaceutical products include SARTATE, SAR-Bombesin and SAR-bisPSMA. SARTATE targets somatostatin receptor 2 (SSTR2) expressing cancers, including neuroblastoma and neuroendocrine tumors. SAR-Bombesin targets gastrin-releasing peptide receptor (GRPr) expressing cancers, including prostate cancer and breast cancer. SAR-bisPSMA targets prostate-specific membrane antigen (PSMA) expressing cancers, including prostate cancer. Its SAR Technology platform employs a superior chelator (cage) for copper used in the diagnosis and treatment of a range of cancers. The technology can be employed for targeted cancer therapy.

image description

Relevant suggested news and content from the site

image description

Only available to Members

Take a free 14 day Market Matters trial – full access to all our reports, portfolios, positions, buy and sell recommendations. Access the latest views on the latest developments from professional money managers. It's free and no payment details are required
For membership options and pricing. Click here
Back to top